Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, STANDARD BIOTOOLS INC. reported revenue of $85M, down 6.2% year over year. Operating margin was -129.2% and net margin -87.8%, on a free-cash-flow margin of -96.9% with capital expenditure at 9.7% of revenue. Every figure is computed directly from LAB's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $85M | -129.2% | -87.8% |
| FY2024 | $91M | -140.1% | -152.6% |
| FY2023 | $106M | -72.0% | -70.2% |
| FY2022 | $98M | -118.6% | -194.1% |
| FY2021 | $131M | -51.7% | -45.4% |
How does LAB compare against its actual peer set?
The full CompsDesk Peer Benchmark Pack: up to 14 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, provenance for every number, board-ready PDF + CSV. One-off $249.
Related in the same sector: A · AEHR · AERG · AEVA · AIRI · ALGN
See LAB benchmarked against two sector peers (free) →
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.